Navigation Links
Alere Inc. Announces Offering of $450 Million of Senior Notes
Date:11/27/2012

WALTHAM, Mass., Nov. 27, 2012 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company") announced today that it intends to offer $450 million of senior notes due 2018 through a private placement, subject to market and other conditions.  The Company intends to use the net proceeds from the offering to finance its announced cash tender offer to repurchase any and all of its outstanding $250.0 million aggregate principal amount of 7.875% Senior Notes due 2016 (the "2016 Notes"), to repay outstanding revolving borrowings in the aggregate principal amount of approximately $97.5 million under its credit agreement and for working capital and other general corporate purposes, including the financing of potential acquisitions or investments, stock repurchases and capital expenditures.  The Company may also use a portion of the net proceeds to pay all or a portion of any post-closing payment, earn-out payment or other form of deferred or contingent consideration for previously completed acquisitions.

The private placement, which is expected to commence immediately, will be to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and outside the United States pursuant to Regulation S under the Securities Act.  The notes are not being registered under the Securities Act.  Unless so registered, the notes may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected offering and the use of proceeds. These statements reflect Alere's current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market and economic conditions. Alere undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE Alere Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
2. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
3. Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
4. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
5. Golden Meditech Announces 2012 / 2013 Interim Results
6. TriReme Announces a New Round of Financing Totalling US$18 Million
7. Baby Quasar announces the launch of its next-gen skin care tool, Clear Rayz, for the treatment of acne
8. Accera Announces Initiation of Clinical Trial for AC-1204
9. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
10. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
11. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... by inspiring human interest stories, which come courtesy of leaders in the nursing and ... the industry, from leading advocates and associations—namely Abilene Christian University. , As the ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of certified ... industries. Aside from its GMP accreditation, Validation Center is also a registered authority ... services and staff. , Validation Center is ISO17025 accredited and only offers its ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to ... Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of ... grilling is their favorite way to cook a hot dog, far outpacing other cooking ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
Breaking Medicine News(10 mins):